Italia Markets closed

Oryzon Genomics S.A. (0RDB.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,9500+0,1220 (+6,67%)
Alla chiusura: 02:48PM BST
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

    At the 36th European College of Neuropsychopharmacology congress (ECNP-2023) MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company presented an update on vafidemstat’s ongoing Phase IIb PORTICO trial in borderline personality disorder (BPD) at the 36th European College of Neu

  • GlobeNewswire

    ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets in the Treatment of Neuronal Pathologies

    Two collaborative projects with public research centers with a global budget of 2.3 million eurosOryzon to receive up to 1.4 million eurosFocused on the discovery and validation of novel biomarkers and epigenetic targets for the treatment of neuronal pathologies MADRID, Spain and BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medica

  • GlobeNewswire

    ORYZON to Provide Corporate Progress Updates at Several Events in October

    East-West Biopharma Summit 36th European College of Neuropsychopharmacology congress (ECNP 2023)Investor Access 2023 EventJefferies Inaugural Biotech CNS/Neuro Summit Roth Capital Partners 2nd Healthcare Opportunities Conference ESMO (European Society for Medical Oncology) 2023 congress MADRID, Spain and BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases